Osteossarcoma

WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours: WHO classification of tumours. 5th ed. vol 3. Lyon, France: IARD Press; 2020

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bone cancer [internet publication].Texto completo

Strauss SJ, Frezza AM, Abecassis N, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021 Dec;32(12):1520-36.Texto completo  Resumo

1. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours: WHO classification of tumours. 5th ed. vol 3. Lyon, France: IARD Press; 2020

2. Azar FM, Canale ST, Beaty JH. Campbell's operative orthopedics. 14th ed. Philadelphia, PA: Elsevier; 2021.

3. Cole S, Gianferante DM, Zhu B, et al. Osteosarcoma: a surveillance, epidemiology, and end results program-based analysis from 1975 to 2017. Cancer. 2022 Jun 1;128(11):2107-18.Texto completo  Resumo

4. Rojas GA, Hubbard AK, Diessner BJ, et al. International trends in incidence of osteosarcoma (1988-2012). Int J Cancer. 2021 Sep 1;149(5):1044-53.Texto completo  Resumo

5. Gianferante DM, Moore A, Spector LG, et al. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma. Cancer Epidemiol. 2024 Oct;92:102432.Texto completo  Resumo

6. NCD Risk Factor Collaboration (NCD-RisC). Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants. Lancet. 2020 Nov 7;396(10261):1511-24.Texto completo  Resumo

7. NCD Risk Factor Collaboration (NCD-RisC). A century of trends in adult human height. Elife. 2016 Jul 26;5:e13410.Texto completo  Resumo

8. Good DA, Busfield F, Fletcher BH, et al. Linkage of Paget disease of bone to a novel region on human chromosome 18q23. Am J Hum Genet. 2002 Feb;70(2):517-25.Texto completo  Resumo

9. Hansen MF, Nellissery MJ, Bhatia P. Common mechanisms of osteosarcoma and Paget's disease. J Bone Miner Res. 1999 Oct;14 Suppl 2:39-44. Resumo

10. Nellissery MJ, Padalecki SS, Brkanac Z, et al. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet. 1998 Sep;63(3):817-24.Texto completo  Resumo

11. Le Vu B, de Vathaire F, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer. 1998 Jul 29;77(3):370-7. Resumo

12. Schwartz B, Benadjaoud MA, Cléro E, et al. Risk of second bone sarcoma following childhood cancer: role of radiation therapy treatment. Radiat Environ Biophys. 2014 May;53(2):381-90.Texto completo  Resumo

13. Hawkins MM, Wilson LM, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst. 1996 Mar 6;88(5):270-8. Resumo

14. Campanacci M. Bone and soft tissue tumors: clinical features, imaging, pathology and treatment. 2nd ed. New York, NY: Springer; 1999.

15. Troisi R, Masters MN, Joshipura K, et al. Perinatal factors, growth and development, and osteosarcoma risk. Br J Cancer. 2006 Dec 4;95(11):1603-7.Texto completo  Resumo

16. Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma. Sarcoma. 2012;2012:627254.Texto completo  Resumo

17. Yamaguchi T, Toguchida J, Yamamuro T, et al. Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res. 1992 May 1;52(9):2419-23.Texto completo  Resumo

18. Overholtzer M, Rao PH, Favis R, et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11547-52.Texto completo  Resumo

19. Miller CW, Aslo A, Won A, et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol. 1996;122(9):559-65. Resumo

20. Mirabello L, Yeager M, Mai PL, et al. Germline TP53 variants and susceptibility to osteosarcoma. J Natl Cancer Inst. 2015 Jul;107(7):djv101.Texto completo  Resumo

21. Mirabello L, Zhu B, Koster R, et al. Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol. 2020 May 1;6(5):724-34.Texto completo  Resumo

22. Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003 May 7;95(9):669-74. Resumo

23. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bone cancer [internet publication].Texto completo

24. Letson D, Falcone R, Muro-Cacho C. Pathologic and radiologic features of primary bone tumors. Cancer Control. 1999 May;6(3):283-93. Resumo

25. Strauss SJ, Frezza AM, Abecassis N, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021 Dec;32(12):1520-36.Texto completo  Resumo

26. Malawer MM, Sugarbaker PH. Musculoskeletal cancer surgery: treatment of sarcomas and allied diseases. Dordrecht: Kluwer Academic Publishers; 2001.

27. Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer. 2008 Aug;51(2):163-70. Resumo

28. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009 Apr 1;115(7):1531-43.Texto completo  Resumo

29. Heck RK Jr, Peabody TD, Simon MA. Staging of primary malignancies of bone. CA Cancer J Clin. 2006 Nov-Dec;56(6):366-75.Texto completo  Resumo

30. Amin MB, Edge S, Greene F, et al. AJCC cancer staging manual, 8th edition. New York: Springer; 2016.

31. Ferrari S, Ruggieri P, Cefalo G, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012 Jun 10;30(17):2112-8. Resumo

32. Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct;17(10):1396-408.Texto completo  Resumo

33. Anderson ME. Update on survival in osteosarcoma. Orthop Clin North Am. 2016 Jan;47(1):283-92. Resumo

34. Davis LE, Bolejack V, Ryan CW, et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019 Jun 1;37(16):1424-31.Texto completo  Resumo

35. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities and trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002 Feb 1;20(3):776-90. Resumo

36. Hendershot E, Pappo A, Malkin D, et al. Tumor necrosis in pediatric osteosarcoma: impact of modern therapies. J Pediatr Oncol Nurs. 2006 Jul-Aug;23(4):176-81. Resumo

37. Beird HC, Bielack SS, Flanagan AM, et al. Osteosarcoma. Nat Rev Dis Primers. 2022 Dec 8;8(1):77. Resumo

38. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19:292-315. Resumo

39. Kager L, Zoubek A, Kastner U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003 May 15;21(10):2011-8. Resumo